ChuanShi Biomedical Completes Over RMB 100 Million Series B Financing to Advance Cardiovascular Diagnostic Innovations
On September 2, 2020, VCBeat (WeChat ID: vcbeat) learned that Shenzhen Chuanshi Biomedical Co., Ltd. (hereinafter referred to as “Chuanshi Biomedical”) announced the completion of its Series B financing round, which was led bySherpa Capital Leads Investment, with Yuanzhi Fuhai Participating(Series A Shareholders),Capital Operation Scale Exceeds 100 Million Yuan。
ChuanShi Bio was established in Shenzhen in 2017, focusing on the diagnosis and prevention of cardiovascular and cerebrovascular diseases. The company is committed to building an innovation-driven, globally oriented Chinese medical device brand. Since August 2017, renowned professional venture capital firms such as Xiantong Capital, Tsinghua Lihexin, Oriental Fortune Capital, CAS Star, Kaiying Capital, and Yuanzhi Fuhai have successively joined ChuanShi Bio’s shareholder register. With the addition of Sherpa Partners in this Series B financing round, ChuanShi Bio’s shareholder lineup has become even more prestigious.
Chuan Shi Bio boasts strong scientific research and innovation capabilities, with its independently developed "Yanxing" series of coagulation analysis products,Pioneering Integration of the Two Major Schools of Coagulation Testing in the Industry, decisively breaking the prevailing paradigm of technology-following in niche product R&D and emerging as a pioneer in application innovation within the coagulation analysis field. Notably, the ChuanShi Bio YX (Yanxing)-3000 features comprehensive forward design, enabling its precision, speed, and reliability to reach top-tier international standards; the product has already been launched on the market.
Dr. Zhang Huali, General Manager of Chuanshi BiotechIt was stated that the Series B financing has provided Chuanshi Biotech with ample cash flow. The company will systematically build up its product marketing and distribution channels, while sequentially launching the “Yanxing Series” products to comprehensively meet the needs of customers at all levels.
“Transworld Biotech will advance its R&D layout for innovative medical devices in the field of diagnosis and prevention of cardiovascular and cerebrovascular diseases, in accordance with its established corporate strategy.”Introduction to Dr. Zhang HualiWith ample capital support, Transcenta Holding’s pioneering distributed pipeline analysis system is set to accelerate its market debut. Adopting a novel analytical model architecture, this system will elevate Transcenta Holding’s product innovation efficiency to new heights and deliver a comprehensive innovative experience for customers.
Sherpa Investment is a specialized healthcare investment fund established in 2018. The core team members have collaborated for many years, boasting extensive investment experience and an outstanding track record in China’s healthcare industry. Committed to serving as professional guides behind the climbers, the team aims to empower entrepreneurs to scale the peaks of their careers.
Shenzhen Yuanzhi Fuhai Investment Management Co., Ltd. is a large-scale M&A fund management company jointly established by the Shenzhen State-owned Assets Supervision and Administration Commission, Oriental Fuhai, and renowned financial institutions. It was registered and established in Qianhai, Shenzhen, in February 2013. The company focuses on mergers, acquisitions, and integration within strategic emerging industries. It has assembled a team of outstanding professionals in finance, investment, M&A, risk management, and corporate governance, with its core management team possessing over ten years of practical experience in equity investment and mergers and acquisitions.